Kymera Therapeutics (NASDAQ: KYMR) will announce topline results from the BroADen Phase 1b trial of KT-621, an oral STAT6 degrader for moderate to severe atopic dermatitis, on Monday, December 8, 2025.
A press release will be issued at 7:00 a.m. ET, followed by a video conference call and webcast at 8:00 a.m. ET. A replay and presentation will be available after the event. Investors can register via the company website at www.kymeratx.com under News and Events.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.